GS方案、PD1免疫疗法联合益生菌治疗胰腺癌根治术后患者的临床疗效<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2025.03.002

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1236 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the clinical efficacy of the GS regimen (gemcitabine combined with tegafur) and PD1 immunotherapy combined with probiotics in patients after pancreatic cancer resection.【Methods】 Eighty patients who underwent pancreatic cancer resection were randomly divided into two groups, A and B, with 40 cases in each group. Group B received the GS regimen combined with PD1 immunotherapy, while Group A received the same treatment as Group B, but with the addition of probiotics. The clinical efficacy, pre-treatment and post-treatment inflammatory indicators [neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR)], NK cells and T cell subgroups (CD3⁺, CD4⁺), tumor markers [carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125)], and adverse reactions were compared between the two groups.【Results】 The total effective rate of Group A was 72.50%, which was higher than Group B's 50.00% (P<0.05). After treatment, NLR, SII, and PLR decreased in both groups (P< 0.05), with Group A having significantly lower values than Group B (P< 0.05). Tumor markers (CA19-9, CEA, CA125) also decreased in both groups after treatment (P< 0.05), with Group A showing lower levels than Group B (P< 0.05). NK cells, CD3⁺, and CD4⁺ levels increased in both groups (P< 0.05), with Group A showing higher values than Group B (P< 0.05). The total incidence of adverse reactions in Group A was 30.00%, which was lower than Group B's 55.00% (P< 0.05).【Conclusion】 The GS regimen combined with PD1 immunotherapy and probiotics can improve immune function, lower tumor marker levels, and reduce the incidence of adverse reactions in patients after pancreatic cancer resection.

Key words： Pancreatic Neoplasms Immunotherapy Lactobacillus Rhamnosus Treatment Outcome

Received: 29 May 2024

PACS:

R735.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.03.002 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I3/373

[1] 白阳,周洪兴,姜玉,等. N-myc下游调节基因对胰腺癌细胞增殖、侵袭及迁移的影响及其机制研究[J].中国现代医学杂志,2022,32(12):39-44.
[2] 周文策,张辉,李昕,等. 胰腺癌免疫治疗的前沿与未来[J].肿瘤防治研究,2023,50(4):338-344.
[3] 陈恬.基于微生物组学的胰腺癌患者口腔及肠道菌群研究[D].上海:中国人民解放军海军军医大学,2020.
[4] 钱云,黄子隽,刘振宇,等. 益生菌抗消化系统恶性肿瘤发生发展的相关机制研究进展[J].中华内科杂志,2022,61(10):1167-1171.
[5] 中国抗癌协会胰腺癌专业委员会. 胰腺癌综合诊治指南(2018版)[J].中华外科杂志,2018,56(7):481-494.
[6] 林泽宇,曾海平,陈记财,等. 胸腔单孔辅助腹腔镜经腹膈肌入路“五步法”手术用于SiewertⅡ型食管胃结合部腺癌No.111淋巴结清扫的可行性[J].中华胃肠外科杂志,2023,26(4):339-345.
[7] 胡鑫明,古军,车宪平,等. RECIST 1·1和RECIST 1·0标准对晚期肾细胞癌靶向治疗疗效评价的比较[J].现代泌尿生殖肿瘤杂志,2019,11(2):71-75.
[8] 陈靖,赵翠翠. 胰腺癌流行现状与病因机制分析[J].国际生物医学工程杂志,2022,45(4):340-344.
[9] 徐玉,何海涛,魏志力,等. 神经元表达发育下调基因9诊断胰腺癌及其对患者预后的预测价值[J].医学临床研究,2023,40(5):735-737.
[10] 侯君慧,徐飞,丛明慧,等. 认知领悟结合身心放松训练对胰腺癌患者癌因性疲乏指数与睡眠质量的影响[J].医学临床研究,2022,39(7):1101-1103.
[11] 汪雪媛. 胰腺癌患者肠道菌群组成谱和功能分析[D].海口:海南医学院,2023.
[12] 万梦园,刘书娟,刘晶晶,等. 术前系统免疫炎症指数与胰腺癌患者预后的关系[J].实用医学杂志,2021,37(19):2482-2486.
[13] 马晨哲,王霄,杨波,等. 微生物与胰腺癌相关性的研究进展[J].兰州大学学报(医学版),2023,49(12):76-81.
[14] 牛婷,郑明辉,邵成浩. 人体微生物群在胰腺癌中的研究现状与进展[J].中华消化杂志,2023,43(6):427-429.
[15] 涂希晨. 胰腺癌患者肠道微环境的研究[D].湖南:湖南师范大学,2020.